Skip to main content

Table 5 Chemotherapy regimens received by patients in the non-cisplatin group

From: Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy — a cohort study

Type of chemotherapy Number of patients (%) N = 200
Capecitabine + Oxaliplatin/5-FU + Leucovorin + Oxaliplatin/Epirubicin + Oxaliplatin + Capecitabine 34 (17)
5-FU + Irinotecan + Leucovorin/5-FU + Irinotecan + Leucovorin + Cetuximab/Irinotecan + Cetuximab 18 (9)
Doxorubicin + Cyclophophamide/5-FU + Epirubicin + Cyclophophamide/Epirubicin + Cyclophophamide 24 (12)
Paclitaxel/Paclitaxel + Herceptin 22 (11)
Docetaxel/Docetaxel + Herceptin 26 (13)
Adrimacycin + Ifosfamide 8 (4)
Carboplatin + Paclitaxel 34 (17)
CHOP/ABVD (Cyclophosphamide + Adriamycin + Vincristine + Prednisone)/(Adriamycin + Bleomycin + Vinblastine + Dacarbazine) 12 (6)
VAC alternating with IE (Vincristine + Adriamycin + Cyclophosphamide alternating with Ifosfamide + Etoposide) 4 (2)
5-FU + Oxaliplatin + Irinotecan + Leucovorin 8 (4)
Gemcitabine 6 (3)
Carboplatin + Gemcitabine 2 (1)
Others 2 (1)